Lantheus (NASDAQ:LNTH) Shares Gap Up - Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $92.66, but opened at $96.00. Lantheus shares last traded at $93.37, with a volume of 74,311 shares.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LNTH. Truist Financial reissued a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target on the stock. JMP Securities cut their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday. They issued a "buy" rating and a $143.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Lantheus Stock Performance

The company's 50-day simple moving average is $97.31 and its two-hundred day simple moving average is $98.28. The firm has a market cap of $6.34 billion, a PE ratio of 15.17 and a beta of 0.45.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the 3rd quarter worth $25,000. Signaturefd LLC raised its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. lifted its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $51,000. Finally, GAMMA Investing LLC raised its position in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 146 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.